Compare Apollo Global Management Ord Shs (APO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Novo Nordisk A/S — how do they compare? Apollo Global Management Ord Shs trades at $138.02 (market cap $82.84B), while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Apollo Global Management Ord Shs's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| APO | NVO | |
|---|---|---|
Market Cap | $82.84B | $207.85B |
Sector | Financials | Health |
52-Week High | $152.70 | $63.98 |
52-Week Low | $100.30 | $35.29 |
Enterprise Value | -$168.65B | $222.55B |
Dividend Yield | 1.6% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $132.02, up 3.59% in 24 hours, with strong technical momentum as it approaches resistance near $134. The company reported mixed Q2 2026 earnings, missing EPS estimates but achieving record fee-related earnings of $785 million (Seeking Alpha, August 4, 2026). Fundamentals show robust revenue growth, with 2025 revenue at $32.05 billion, though net income margins have declined to 5.22% from prior peaks.
Outlook remains positive with an 82% analyst buy rating and a $151.50 price target, but risks include high P/E of 49.92 and exposure to private credit market volatility. Recent news highlights strategic AI infrastructure deals, such as a $2.6 billion partnership with Yankee Global Enterprises (Business Wire, August 11, 2026), supporting long-term growth amid competitive pressures.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
